Thu. 9 May 2024, 7:16am ET
Benzinga
Earnings, Earnings Misses, News
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.67) by 4.48 percent. This is a 37.25 percent decrease over losses of $(0.51) per share from the same period last year.